Dutch biotechnology company Crucell N.V. has signed a non-exclusive PER.C6 technology license agreement with Vaxin, Inc of Birmingham, Alabama. This license agreement allows Vaxin to use PER.C6 technology for research, development and commercialization of recombinant adenoviral vaccines against certain respiratory viruses.
Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on sales of vaccines. Further financial details were not disclosed, a company release said.
Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria and West Nile virus. The company's development programmes include collaborations with Aventis Pasteur for influenza vaccines, the US National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine.